Dr. Reddy's Reports Q3 FY26 Profitability Decline and USFDA Denosumab Biosimilar CRL
RDY is trading near its 52-week low of $12.26 (8.6% above the low).
Summary
Dr. Reddy's Laboratories reported Q3 FY26 results with modest revenue growth but a significant decline in diluted EPS and EBITDA margins year-over-year, alongside a Complete Response Letter from the USFDA for its denosumab biosimilar.
Key Events · Earnings and Guidance · RDY
-
Q3 FY26 Financial Performance
Revenues grew 4.4% year-over-year to ₹8,727 Cr, but diluted EPS declined 14% to ₹14.5, and EBITDA margin decreased to 23.5% from 27.5% in the prior year.
-
Regulatory Setback for Denosumab Biosimilar
The company received a Complete Response Letter (CRL) from the USFDA for its denosumab biosimilar BLA, citing observations at Alvotech's facility.
-
USFDA Observations
An inspection at the FTO-SEZ PU-01 formulations facility resulted in five Form 483 observations, though a response has been submitted.
-
Strategic Collaboration
Dr. Reddy's entered a strategic collaboration with Immutep for the commercialization of an oncology drug, Eftilagimod Alfa, in key Emerging Markets, including an upfront payment of US$20 million and potential milestones up to US$350 million.
Analysis · RDY · Life Sciences
Dr. Reddy's Laboratories' Q3 FY26 results indicate a challenging quarter with declining profitability metrics despite modest revenue growth. The significant year-over-year drop in diluted EPS and EBITDA margins, coupled with product-specific headwinds and pricing pressure in North America, suggests operational challenges. The Complete Response Letter from the USFDA for the denosumab biosimilar is a notable setback, delaying a key product's market entry. While new product launches and a strategic collaboration offer future potential, the immediate financial performance and regulatory hurdles present a negative outlook for investors.
At the time of this filing, RDY was trading at $13.31 on NYSE in the Life Sciences sector, with a market capitalization of approximately $10.7B. The 52-week trading range was $12.26 to $16.17. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.